Showing promise in the landscape of weight management therapy, retatrutide represents a different strategy. Unlike many existing medications, retatrutide functions as a double agonist, concurrently affecting both GLP-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The concurrent activation fosters multiple h